舌下抗原特异性免疫治疗过敏性鼻炎的临床疗效评价

Clinical evaluation of sublingual antigen-specific immunotherapy for allergic rhinitis

目的探讨舌下抗原特异性免疫治疗过敏性鼻炎的临床疗效,为临床上过敏性鼻炎治疗方案的选择提供依据。方法选择2015年6～12月期间惠州市第三人民医院耳鼻喉科收治的122例过敏性鼻炎患者为研究对象,根据随机数表法分为观察组和对照组,每组61例,对照组患者予常规应用开瑞坦和内舒拿治疗,观察组在此基础上联合应用舌下抗原特异性免疫治疗,总疗程为2年。比较两组患者治疗前后过敏性鼻炎症状评分和药物应用评分的变化,记录治疗期间药物不良反应发生情况。结果治疗后,观察组患者的鼻炎症状评分和药物应用评分分别为(2.74±0.93)分、(0.45±0.28)分,明显低于对照组的(3.46±1.18)分、(0.96±0.42)分,差异均有统计学意义(P<0.05);两组患者治疗期间均无严重不良反应发生。结论舌下抗原特异性免疫治疗过敏性鼻炎可以有效缓解患者的临床症状,具有确切的疗效和较好的安全性。

Objective To investigate the clinical efficacy of sublingual antigen-specific immunotherapy for allergic rhinitis, and to provide basis for the selection of clinical allergic rhinitis. Methods A total of 122 patients with allergic rhinitis treated in Department of E.N.T, the Third People＇s Hospital of Huizhou form June 2015 to December 2015 were selected and divided into observation group and control group according to random number table, with 61 patients in each group. Patients in the control group were treated with Clarityne（Loratadine Tablets） and Nasonex, and the observation group applied sublingual antigen-specific immunotherapy additionally. The total course of treatment was two years.The symptom score and drug application score of allergic rhinitis before and after treatment were compared between the two groups, and the occurrence of adverse drug reactions was recorded during the treatment. Results After treatment, the symptoms score and drug application score of the patients in the observation group were（2.74±0.93） and（0.45±0.28） respectively, which were significantly lower than（3.46±1.18） and（0.96±0.42） of the control group（P〈0.05）. There were no serious adverse reactions during the treatment in the two groups. Conclusion Sublingual antigen-specific immunotherapy for allergic rhinitis can effectively alleviate the clinical symptoms of patients, with definite efficacy and good safety.